EN
简体
繁体
EN
简体
繁体
About Us
Company Profile
Milestones
Our Team
Investors
Partnership & Recognition
Contact Us
CANbridge in Rare Disease Community
Pipeline & Products
Pipeline
Rare Diseases
Gene Therapy
Other Onc.
Approved Products
Livmarli®
Hunterase®
Nerlynx®
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Corporate Governance
Stock Information
Presentations & Webcasts
Analyst Coverage
Financial Calendar
Email Alert and IR Contact
Electronic Dissemination of Corporate Communications
Media & News
Media Reports
Press Release
Corporate Culture & Career
Corporate Culture
Open Positions
Back to Media & News
New Gene Therapy Shows Potential for Safety, Efficacy in Mouse Model
2022/05/11
Previous
Next
Back to Media & News
Previous
